THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING
Life Sciences: Biotech

2 new treatments for Crohn's due soon

The rheumatoid arthritis drug Humira could be worth $500 million a year as a treatment for Crohn's. The rheumatoid arthritis drug Humira could be worth $500 million a year as a treatment for Crohn's.
By Diedtra Henderson
Globe Staff / February 19, 2007

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size – +

WASHINGTON -- For patients suffering from a severe form of Crohn's disease, a remedy already on the shelf to treat other maladies and a brand-new drug could offer new hope. (Full article: 730 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $4.95 1 article
  • $9.95 4 articles
  • $25.95 Monthly